Paper41333366
Clinical outcomes of patients with advanced EGFR mutated nonsquamous cell lung carcinoma treated at a tertiary care hospital.
Ahmed F and 7 others. Ecancermedicalscience, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Clinical outcomes of patients with advanced EGFR mutated nonsquamous cell lung carcinoma treated at a tertiary care hospital. Papers, record 41333366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41333366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical outcomes of patients with advanced EGFR mutated nonsquamous cell lung carcinoma treated at a tertiary care hospital.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37937763 | Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37937763 | PubMed |
| 2 | 24663503 | Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? | Cancer Chemother Pharmacol | 2014 | https://conductscience.org/library/papers/24663503 | PubMed |
| 3 | 26579470 | Mechanisms of resistance to EGFR tyrosine kinase inhibitors. | Acta Pharm Sin B | 2015 | https://conductscience.org/library/papers/26579470 | PubMed |
| 4 | 11784875 | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. | N Engl J Med | 2002 | https://conductscience.org/library/papers/11784875 | PubMed |
| 5 | 31751012 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31751012 | PubMed |
| 6 | 23594426 | Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. | J Natl Cancer Inst | 2013 | https://conductscience.org/library/papers/23594426 | PubMed |
| 7 | 31218108 | Survival and prognostic factors in non-small cell lung cancer patients with mutation of the EGFR gene treated with tyrosine kinase inhibitors in a peruvian hospital. | Am J Cancer Res | 2019 | https://conductscience.org/library/papers/31218108 | PubMed |
| 8 | 29371589 | Cell death-based treatment of lung adenocarcinoma. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/29371589 | PubMed |
| 9 | 29079040 | Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. | Arch Bronconeumol (Engl Ed) | 2018 | https://conductscience.org/library/papers/29079040 | PubMed |
| 10 | 36817181 | Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study. | Lancet Reg Health Eur | 2023 | https://conductscience.org/library/papers/36817181 | PubMed |
| 11 | 34564820 | Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC. | Target Oncol | 2021 | https://conductscience.org/library/papers/34564820 | PubMed |
| 12 | 23078958 | First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/23078958 | PubMed |
| 13 | 19680293 | Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. | Oncogene | 2009 | https://conductscience.org/library/papers/19680293 | PubMed |
| 14 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 15 | 29496250 | Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. | Lung Cancer | 2018 | https://conductscience.org/library/papers/29496250 | PubMed |
| 16 | 37279591 | Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. | Jpn J Clin Oncol | 2023 | https://conductscience.org/library/papers/37279591 | PubMed |
| 17 | 37196999 | Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study. | J Cancer Allied Spec | 2023 | https://conductscience.org/library/papers/37196999 | PubMed |
| 18 | 31564718 | Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. | Br J Cancer | 2019 | https://conductscience.org/library/papers/31564718 | PubMed |
| 19 | 18316005 | Small cell lung cancer. | Mayo Clin Proc | 2008 | https://conductscience.org/library/papers/18316005 | PubMed |
| 20 | 30207593 | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2018 | https://conductscience.org/library/papers/30207593 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41333366
GET https://conductscience.org/api/papers/v1/41333366/references?page=2